10-chloro-6-(4-(2-hydroxyethyl)piperazin-1-yl)-12H-thiochromeno [2, 3-c]quinolin-12one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 10-chloro-6-(4-(2-hydroxyethyl)piperazin-1-yl)-12H-thiochromeno [2, 3-c]quinolin-12one
• 英文别名: 10-Chloro-6-[4-(2-hydroxyethyl)piperazin-1-yl]thiochromeno[2,3-c]quinolin-12-one；10-chloro-6-[4-(2-hydroxyethyl)piperazin-1-yl]thiochromeno[2,3-c]quinolin-12-one
• 化学式: C₂₂H₂₀ClN₃O₂S
• 分子量: 425.939
• InChiKey: QRAUAOIXBNKFCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4-氯苯基硫酚)乙酸 在 sodium acetate 、 sodium carbonate 、 三氯氧磷 作用下， 以 二甲基亚砜 为溶剂， 反应 59.0h， 生成 10-chloro-6-(4-(2-hydroxyethyl)piperazin-1-yl)-12H-thiochromeno [2, 3-c]quinolin-12one
  参考文献：
  名称：

  Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents

  摘要：

  A series of tetracyclic heterocyclic azathioxanthones were synthesized and evaluated for cell proliferations, topoisomerase inhibitions, and NCI-60 cell panel assay, respectively. Compounds 5, 7, 8, 16, and 19 were selected for topoisomerase assay after MTT assay. 7 not only showed cytotoxic effect (IC50 2.84 +/- 0.64 mu M) in PC-3 cells but also revealed topoisomerases inhibition with IC50 (10-25 mu M) and increased apoptotic cleavage of PARP and caspase 3 activity. The overall of novel azathioxanthones with different cytostatic and cytotoxic activities should be further developed as new potential candidates for anticancer drugs. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.09.050

文献信息

• Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors
  申请人：National Defense Medical Center

  公开号：EP3002287B1

  公开（公告）日：2018-01-31
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER
  申请人：Del Mar Pharmaceuticals

  公开号：EP3125920A2

  公开（公告）日：2017-02-08
• EP3125920B1
  申请人：——

  公开号：EP3125920B1

  公开（公告）日：2020-12-23
• COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER
  申请人：Delmar Pharmaceuticals, Inc.

  公开号：EP3294284A1

  公开（公告）日：2018-03-21
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES
  申请人：Del Mar Pharmaceuticals

  公开号：US20160008316A1

  公开（公告）日：2016-01-14

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.